SCHEMBL3205488

SCHEMBL3205488

COc1c(CO)ccc([N+](=O)[O-])c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
TPMT P51580 1/20 0.40
TXNRD1 Q16881 2/20 0.39
TTR P02766 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14092102 0.87 TDP1 (0.41) ALDH1A1TDP1TPMTTXNRD1TTR
SCHEMBL2031172 0.85 KMT2A (0.39) ALDH1A1TDP1TPMTTXNRD1TTR
SCHEMBL9277125 0.85 TDP1 (0.43) ALDH1A1TDP1TPMTTXNRD1TTR
SCHEMBL5201436 0.85 ALDH1A1 (0.47) ALDH1A1TDP1KMT2AMEN1SMN1; SMN2
SCHEMBL31347487 0.85 ALDH1A1 (0.47) ALDH1A1TDP1KMT2AMEN1SMN1; SMN2
SCHEMBL18138432 0.84 ALDH1A1 (0.42) ALDH1A1TDP1TPMTTXNRD1KMT2A
SCHEMBL8725594 0.83 ALDH1A1 (0.41) ALDH1A1TDP1TPMTTXNRD1KMT2A
SCHEMBL12776959 0.82 CYP1A2 (0.53) ALDH1A1TDP1TPMTKMT2AMEN1
SCHEMBL5297157 0.78 TAAR1 (0.41)
SCHEMBL12776956 0.77 ALDH1A1 (0.42) ALDH1A1TDP1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437749-B1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2013-07-17 EP claimed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP claimed
US-11427542-B2 Compounds for treatment of cardiac arrhythmias and heart failure ELEX BIOTECH, INC. (US) 2022-08-30 US disclosed
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2021-05-13 US disclosed
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2021-05-13 US disclosed
EP-3774734-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE Elex Biotech, Inc. (US) 2021-02-17 EP disclosed
CN-111936466-A Compounds for the treatment of cardiac arrhythmias and heart failure 埃利克斯生物技术公司 2020-11-13 CN disclosed
WO-2019191502-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2019-10-03 WO disclosed
WO-2019191502-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2019-10-03 WO disclosed
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 US disclosed
US-7279117-B2 Electrolytic capacitor and electrolyte solution for use in an electrolytic capacitor RUBYCON CORPORATION (JP) 2007-10-09 US disclosed
US-20070171595-A1 Electrolytic capacitor and electrolyte solution for use in an electrolytic capacitor RUBYCON CORPORATION (JP) 2007-07-26 US disclosed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 US disclosed
US-20050094352-A1 Electrolytic capacitor and electrolitic solution for driving electrolytic capacitor RUBYCON CORPORATION (JP) 2005-05-05 US disclosed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 US disclosed
EP-1460660-A1 ELECTROLYTIC CAPACITOR AND ELECTROLITIC SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-09-22 EP disclosed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE RYR2, RYR1, CACNA1F ALDH1A1 2527/4885TDP1 1569/4885TPMT 487/4885
US-11427542-B2 Compounds for treatment of cardiac arrhythmias and heart failure RYR2, RYR1, CACNA1F ALDH1A1 2527/4885TDP1 1569/4885TPMT 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.